Interferon-stimulated gene pathways in the treatment of viral hepatitis

Future Virology

Volumn 7, Issue 4, 2012, Pages 361-369

  Burlone, Michela E ^a   Minisini, Rosalba ^a   Pirisi, Mario ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

hepatitis B virus; hepatitis C virus; interferon stimulated gene; ISG15; type III interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON TYPE III; INTERLEUKIN 28B; JANUS KINASE; PEGINTERFERON ALPHA; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; STAT PROTEIN; STAT1 PROTEIN; UBIQUITIN; UBIQUITIN LIKE PROTEIN ISG15; UNCLASSIFIED DRUG; VIRUS RNA;

CELL MEMBRANE; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84859397045     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.21     Document Type: Review

References (73)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147(927), 258-267 (1957
2. Nagano Y, Kojima Y. [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. C. R. Seances Soc. Biol. Fil. 148(19-20), 1700-1702 (1954
3. Baum A, García-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 38(5), 1283-1299 (2010
4. Fensterl V, Sen GC. Interferons and viral infections. BioFactors 35(1), 14-20 (2009
5. Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. Chem. 280(17), 16739-16747 (2005
6. Pfaller CK, Li Z, George CX, Samuel CE. Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response. Curr. Opin. Immunol. 23(5), 573-582 (2011
7. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14(1), 111-116 (2002
8. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5(7), 730-737 (2004
9. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778-809, (2001
10. Heim MH. Intracellular signalling and antiviral effects of interferons. Dig. Liver Dis. 32(3), 257-263 (2000
11. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8(7), 559-568 (2008
12. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 21(4), 237-251 (2010
13. Wolk K, Witte K, Witte E et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc. Biol. 83(5), 1181-1193 (2008
14. Witte K, Gruetz G, Volk HD et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10(8), 702-714 (2009
15. Weber F, Haller O. Viral suppression of the interferon system. Biochimie 89(6-7), 836-842 (2007
16. Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J. Virol. 75(3), 1332-1338 (2001
17. Mihm S, Frese M, Meier V et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84(9), 1148-1159 (2004
18. Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melén K, Julkunen I. Impaired antiviral response in human hepatoma cells. Virology 263(2), 364-375 (1999
19. Pirisi M, Fabris C, Toniutto P et al. Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C. Dig. Dis. Sci. 42(4), 767-771 (1997
20. Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J. Med. Virol. 70(4), 562-570 (2003
21. Ulsenheimer A, Gerlach JT, Jung M-C et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41(3), 643-651 (2005
22. Takahashi K, Asabe S, Wieland S et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl Acad. Sci. USA 107(16), 7431-7436 (2010
23. Lai WK, Curbishley SM, Goddard S et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J. Hepatol. 47(3), 338-347 (2007
24. Harvey CE, Post JJ, Palladinetti P et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 74(3), 360-369 (2003
25. Minisini R, Giarda P, Grossi G et al. Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome. J. Gastroenterol. 46(11), 1307-1315 (2011
26. Borgogna C, Toniutto P, Smirne C et al. Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. Histopathology 54(7), 837-846 (2009
27. Antonelli G, Simeoni E, Turriziani O et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J. Interferon Cytokine Res. 19(3), 243-251 (1999
28. Meier V, Mihm S, Ramadori G. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-a. J. Med. Virol. 62(3), 318-326 (2000
29. Macquillan GC, De Boer WB, Platten MA et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J. Med. Virol. 68(2), 197-205 (2002
30. Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128(5), 1437-1444 (2005
31. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46(5), 1548-1563 (2007
32. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105(19), 7034-7039 (2008
33. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005
34. Loo Y-M, Owen DM, Li K et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl Acad. Sci. USA 103(15), 6001-6006 (2006
35. Cheng G, Zhong J, Chisari FV. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc. Natl Acad. Sci. USA 103(22), 8499-8504 (2006
36. Lenschow DJ, Lai C, Frias-Staheli N et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104(4), 1371-1376 (2007
37. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 91(2), 382-388 (2010).
38. Kim M-J, Hwang S-Y, Imaizumi T, Yoo J-Y. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 82(3), 1474-1483 (2008
39. Arnaud N, Dabo S, Akazawa D et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7(10), E1002289 (2011
40. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344), 481-485 (2011
41. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J. Virol. 85(24), 12881-12889 (2011
42. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4(1), 63-68 (2003
43. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4(1), 69-77 (2003
44. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79(6), 3851-3854 (2005
45. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol. J. 2, 80 (2005
46. Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52(3), 822-832 (2010
47. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009
48. Suppiah V, MoldoVan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009
49. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009
50. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52(1), 33-37 (2010
51. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345, 1345.E1-E7 (2010
52. Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139(5), 1586-1592, 1592.E1 (2010
53. Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ et al. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Clin. Pharmacol. Ther. 90(5), 712-721 (2011
54. Abe H, Hayes CN, Ochi H et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 54(6), 1094-1101 (2011
55. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2), 499-509 (2010
56. Abe H, Hayes CN, Ochi H et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J. Med. Virol. 83(9), 1597-1607 (2011
57. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6), 1888-1896 (2010
58. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3), 1021-1031 (2011
59. Wheelock EF, Schenker S, Combes B. Absence of circulating interferon in patients with infectious and serum hepatitis. Exp. Biol. Med. 128(1), 251-253 (1968
60. Taylor PE, Zuckerman AJ. Non-production of interfering substances by serum from patients with infectious hepatitis. J. Med. Microbiol. 1(2), 217-219 (1968
61. Kato Y, Nakagawa H, Kobayashi K, Hattori N, Hatano K. Interferon production by peripheral lymphocytes in HBsAg-positive liver diseases. Hepatology 2(6), 789-790 (1982
62. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis B virus. J. Virol. 81(1), 159-165 (2007
63. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126(1), 263-277 (2004
64. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of STAT1. J. Gen. Virol. 88(Pt 12), 3260-3269 (2007
65. Lutgehetmann M, Bornscheuer T, Volz T et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 140(7), 2074-2083.E1-2 (2011).
66. Jaroszewicz J, Ho H, Markova A et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antiviral Ther. 16(6), 915-924 (2011
67. Chan HL-Y, Thompson A, Martinot- Peignoux M et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J. Hepatol. 55(5), 1121-1131 (2011
68. Narumi S, Tominaga Y, Tamaru M et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol. 158(11), 5536-5544 (1997
69. Zhou Y, Wang S, Ma J-W et al. Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes. J. Biol. Chem. 285(16), 12159-12168 (2010
70. You CR, Park SH, Jeong SW et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver 5(4), 506-512 (2011
71. Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int. 31(6), 840-849 (2011
72. Lagging M, Romero AI, Westin J et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44(6), 1617-1625 (2006
73. Beinhardt S, Aberle JH, Strasser M et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 142(1), 78-85.E2 (2012)